Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Return on invested capital
Incyte Corporation's return on invested capital over the twelve months to 30 June 2026 was 60.5%, up 1.9 percentage points from fiscal 2025 (58.6%). Over the past ten years it has ranged from −31.4% (fiscal 2017) to 58.6% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 58.6% | 55.65 |
| FY2024 | 2.90% | (21.91) |
| FY2023 | 24.8% | (6.38) |
| FY2022 | 31.2% | 6.00 |
| FY2021 | 25.2% | 44.75 |
| FY2020 | −19.6% | (66.87) |
| FY2019 | 47.3% | 31.32 |
| FY2018 | 16.0% | 47.36 |
| FY2017 | −31.4% | (65.91) |
| FY2016 | 34.5% | (3.72) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| INCY Incyte Corporation | 60.5% |
| EXEL Exelixis, Inc. compare | 60.5% |
| ASND Ascendis Pharma A/S compare | 15.1% |
| GMAB Genmab A/S Sponsored ADR compare | 6.99% |
| RPRX Royalty Pharma PLC compare | 5.28% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −34.5% |
| BNTX BioNTech SE Sponsored ADR compare | −38.4% |
| INSM Insmed, Inc. compare | −329.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement